<?xml version='1.0' encoding='utf-8'?>
<document id="32187961"><sentence text="Molecular pharmacokinetic mechanism of the drug-drug interaction between genistein and repaglinide mediated by P-gp."><entity charOffset="73-82" id="DDI-PubMed.32187961.s1.e0" text="genistein" /><entity charOffset="87-98" id="DDI-PubMed.32187961.s1.e1" text="repaglinide" /><pair ddi="false" e1="DDI-PubMed.32187961.s1.e0" e2="DDI-PubMed.32187961.s1.e0" /><pair ddi="false" e1="DDI-PubMed.32187961.s1.e0" e2="DDI-PubMed.32187961.s1.e1" /></sentence><sentence text="This study was devised to investigate if P-glycoprotein (P-gp) mediated the drug-drug interaction (DDI) between genistein and repaglinide"><entity charOffset="112-121" id="DDI-PubMed.32187961.s2.e0" text="genistein" /><entity charOffset="126-137" id="DDI-PubMed.32187961.s2.e1" text="repaglinide" /><pair ddi="false" e1="DDI-PubMed.32187961.s2.e0" e2="DDI-PubMed.32187961.s2.e0" /><pair ddi="false" e1="DDI-PubMed.32187961.s2.e0" e2="DDI-PubMed.32187961.s2.e1" /></sentence><sentence text=" When genistein was added, the plasma concentrations of repaglinide in rats were increased"><entity charOffset="6-15" id="DDI-PubMed.32187961.s3.e0" text="genistein" /><entity charOffset="56-67" id="DDI-PubMed.32187961.s3.e1" text="repaglinide" /><pair ddi="false" e1="DDI-PubMed.32187961.s3.e0" e2="DDI-PubMed.32187961.s3.e0" /><pair ddi="false" e1="DDI-PubMed.32187961.s3.e0" e2="DDI-PubMed.32187961.s3.e1" /></sentence><sentence text=" The maximum plasma concentration (Cmax) of repaglinide increased from 70"><entity charOffset="44-55" id="DDI-PubMed.32187961.s4.e0" text="repaglinide" /></sentence><sentence text="80 ± 7" /><sentence text="98 ng/mL to 124" /><sentence text="71 ± 9" /><sentence text="02 ng/mL and the area under the plasma concentration-time curve (AUC) increased from 134" /><sentence text="89 ± 13" /><sentence text="65 μg·h/L to 245" /><sentence text="95 ± 7" /><sentence text="24 μg·h/L" /><sentence text=" Intestinal absorption of repaglinide was markedly enhanced by genistein or P-gp inhibitor verapamil (Ver), both in situ rat jejunal perfusion studies and in vitro transport assays using everted rat intestinal sac preparations"><entity charOffset="26-37" id="DDI-PubMed.32187961.s13.e0" text="repaglinide" /><entity charOffset="63-72" id="DDI-PubMed.32187961.s13.e1" text="genistein" /><pair ddi="false" e1="DDI-PubMed.32187961.s13.e0" e2="DDI-PubMed.32187961.s13.e0" /><pair ddi="false" e1="DDI-PubMed.32187961.s13.e0" e2="DDI-PubMed.32187961.s13.e1" /></sentence><sentence text=" Furthermore, the accumulation of repaglinide in both Caco-2 cells and IEC-6 cells also increased significantly in the presence of genistein and Ver"><entity charOffset="34-45" id="DDI-PubMed.32187961.s14.e0" text="repaglinide" /><entity charOffset="131-140" id="DDI-PubMed.32187961.s14.e1" text="genistein" /><pair ddi="false" e1="DDI-PubMed.32187961.s14.e0" e2="DDI-PubMed.32187961.s14.e0" /><pair ddi="false" e1="DDI-PubMed.32187961.s14.e0" e2="DDI-PubMed.32187961.s14.e1" /></sentence><sentence text=" The transepithelial transport rate of repaglinide from basolateral-to-apical in MDR1-MDCK cells was 3"><entity charOffset="39-50" id="DDI-PubMed.32187961.s15.e0" text="repaglinide" /></sentence><sentence text="6-fold higher than the apical-to-basolateral rate with a net efflux ratio of 1" /><sentence text="92 compared with mock-MDCK cells, which was significantly decreased following co-administration with genistein or Ver"><entity charOffset="101-110" id="DDI-PubMed.32187961.s17.e0" text="genistein" /></sentence><sentence text=" In an intracellular accumulation experiment using Rhodamine 123 as a P-gp substrate, genistein significantly increased the intracellular fluorescence of Rhodamine 123"><entity charOffset="86-95" id="DDI-PubMed.32187961.s18.e0" text="genistein" /></sentence><sentence text=" These results indicated that genistein had an inhibitory effect on the efflux function of P-gp"><entity charOffset="30-39" id="DDI-PubMed.32187961.s19.e0" text="genistein" /></sentence><sentence text=" Through molecular docking assays we further found that genistein could bind to the nucleotide-binding domains (NBD) in the cytoplasm of P-gp, thus affecting the functions of P-gp"><entity charOffset="56-65" id="DDI-PubMed.32187961.s20.e0" text="genistein" /></sentence><sentence text=" In conclusion, genistein inhibited the efflux of repaglinide mediated by P-gp in rats and in vitro"><entity charOffset="16-25" id="DDI-PubMed.32187961.s21.e0" text="genistein" /><entity charOffset="50-61" id="DDI-PubMed.32187961.s21.e1" text="repaglinide" /><pair ddi="false" e1="DDI-PubMed.32187961.s21.e0" e2="DDI-PubMed.32187961.s21.e0" /><pair ddi="false" e1="DDI-PubMed.32187961.s21.e0" e2="DDI-PubMed.32187961.s21.e1" /></sentence><sentence text=" The findings suggested that the DDI between genistein and repaglinide is mediated by P-gp, and a dosage adjustment may be needed when they are co-administered in a clinical setting"><entity charOffset="45-54" id="DDI-PubMed.32187961.s22.e0" text="genistein" /><entity charOffset="59-70" id="DDI-PubMed.32187961.s22.e1" text="repaglinide" /><pair ddi="false" e1="DDI-PubMed.32187961.s22.e0" e2="DDI-PubMed.32187961.s22.e0" /><pair ddi="false" e1="DDI-PubMed.32187961.s22.e0" e2="DDI-PubMed.32187961.s22.e1" /></sentence><sentence text="" /></document>